Vident Advisory LLC Boosts Stock Position in Abbott Laboratories $ABT

Key Points

• Vident Advisory LLC increased its holdings in Abbott Laboratories by 57% during the first quarter, acquiring an additional 19,898 shares, bringing its total to 54,797 shares worth approximately $7.27 million.
• Abbott Laboratories reported $11.14 billion in revenue for its last quarter, exceeding analysts' expectations, with earnings per share hitting the consensus estimate of $1.26.
• The company's quarterly dividend was recently paid at $0.59 per share, representing an annualized dividend of $2.36 with a yield of 1.8%.

Vident Advisory LLC increased its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 57.0% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 54,797 shares of the healthcare product maker's stock after purchasing an additional 19,898 shares during the period. Vident Advisory LLC's holdings in Abbott Laboratories were worth $7,269,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ABT. Hughes Financial Services LLC bought a new position in Abbott Laboratories in the 1st quarter worth $27,000. Abound Financial LLC bought a new position in Abbott Laboratories in the 1st quarter worth $28,000. Elequin Capital LP bought a new position in Abbott Laboratories in the 1st quarter worth $30,000. JCIC Asset Management Inc. bought a new position in Abbott Laboratories in the 1st quarter worth $32,000. Finally, Vision Financial Markets LLC bought a new position in Abbott Laboratories in the 1st quarter worth $33,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Analyst Ratings Changes

ABT has been the subject of several research reports. Evercore ISI upped their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Leerink Partners began coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 price target for the company. Wells Fargo & Company decreased their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research note on Friday, July 18th. Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a research note on Monday, June 16th. Finally, Mizuho increased their price objective on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and an average price target of $144.47.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded up $0.55 during trading on Wednesday, reaching $132.01. 4,747,852 shares of the company traded hands, compared to its average volume of 6,726,949. The firm has a 50 day simple moving average of $130.84 and a 200-day simple moving average of $131.36. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $229.75 billion, a PE ratio of 16.54, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were paid a dividend of $0.59 per share. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.